We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 26, 2022

Ponatinib After Failure of Second-Generation TKIs in Resistant Chronic-Phase CML

American Journal of Hematology


Additional Info

Disclosure statements are available on the authors' profiles:

American Journal of Hematology
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia
Am. J. Hematol 2022 Aug 12;[EPub Ahead of Print], HM Kantarjian, E Jabbour, M Deininger, E Abruzzese, J Apperley, J Cortes, C Chuah, DJ DeAngelo, J DiPersio, A Hochhaus, J Lipton, FE Nicolini, J Pinilla-Ibarz, D Rea, G Rosti, P Rousselot, NP Shah, M Talpaz, S Srivastava, X Ren, M Mauro

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading